TEVA Institutional Ownership - Teva Pharmaceutical Industries Ltd. (NYSE) Stock
Generic Drug Lawsuit Could Mean Big Fines for Teva, Mylan: UBS
A Look At Teva's Paragard IUD Asset Sale To Cooper Companies, From Both Sides
Suffering from missteps, drugmaker Teva struggles to heal own ills | The Times of Israel
Teva shares hit 19-year low after opioid settlement, analyst downgrades | Fierce Pharma
UBS applauds Teva for Auspex acquisition - Globes
UBS cuts estimate of Teva's opioid liability - Globes
Teva Pharmaceuticals Agrees To $85 Million Settlement In Opioid Case. - The Medical Times
Teva completes $3.2b acquisition of Auspex - Globes
Teva Plummets on Downgrade Following $85M Opioid Settlement - TheStreet
Rebounding Teva is 'too cheap to ignore,' upbeat analysts say | Fierce Pharma
Rhode Island takes Teva to trial in multibillion-dollar opioid case | Nasdaq
UBS — EMMA KOLB
Teva's Legal Overhang Triggers UBS Downgrade, Near-Halving Of Price Target
Exclusive: UBS in talks with China Life for China asset management JV - sources - Headquarters Finance
UBS barberer en tredjedel af kursmål for Teva
Most Active Foreign Bonds 21.05.2021 – Teva Pharma, Gazprom, New York Life, Deutsche Bahn, Russian Railways, UBS London Branch – Financial Markets Blog
UBS: Teva raises Copaxone double dose price - Globes
Teva jumps after Wall Street upgrades, analysts say stock 'too cheap to ignore'
Storbank blåstempler Kåre Schultz' plan for Teva: Aktien er »for billig til at ignorere«
UBS raises Teva price target - Globes
